2024
Activated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, PMCID: PMC11305967, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markers
2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose C, Hellqvist Å, Roseti S, Molfino N, Llanos J, Martin N, Bowen K, Griffiths J, Parnes J, Colice G. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal Of Respiratory And Critical Care Medicine 2023, 208: 13-24. PMID: 37015033, PMCID: PMC10870853, DOI: 10.1164/rccm.202210-2005oc.Peer-Reviewed Original ResearchConceptsAsthma exacerbation rateUncontrolled asthmaExacerbation rateSecondary outcomesClinical trialsOverall populationRelevant subgroupsMeaningful reductionEfficacy of tezepelumabExacerbation-related hospitalizationsSafety of tezepelumabPlacebo-controlled trialEmergency department visitsInflammatory biomarker levelsNitric oxide levelsAdverse eventsAllergy statusBaseline bloodClinical characteristicsDepartment visitsPooled analysisNAVIGATOR trialBiomarker levelsOxide levelsTezepelumab
2022
Asthma exacerbations during the pandemic: Time to rethink clinical markers
Ortega H, Katz L, Chupp G. Asthma exacerbations during the pandemic: Time to rethink clinical markers. Journal Of Allergy And Clinical Immunology Global 2022, 2: 97-100. PMID: 36281240, PMCID: PMC9581642, DOI: 10.1016/j.jacig.2022.09.003.Peer-Reviewed Original ResearchPrimary end pointAsthma exacerbationsClinical studiesClinical markersEnd pointCOVID-19 pandemicClinical trial enrollmentCoronavirus disease 2019 (COVID-19) pandemicNitric oxide levelsRecent clinical reportsDisease 2019 pandemicPrior exacerbationsPlacebo armFuture exacerbationsTrial enrollmentClinical trialsOxide levelsExacerbationClinical reportsClinical practiceCOVID-19Prior yearPandemicEnrollmentBest predictor
2005
Yoga intervention for adults with mild-to-moderate asthma: a pilot study
Sabina AB, Williams A, Wall HK, Bansal S, Chupp G, Katz DL. Yoga intervention for adults with mild-to-moderate asthma: a pilot study. Annals Of Allergy Asthma & Immunology 2005, 94: 543-548. PMID: 15945557, DOI: 10.1016/s1081-1206(10)61131-3.Peer-Reviewed Original ResearchConceptsModerate asthmaYoga interventionOutcome measuresMasked clinical trialRescue inhaler useHealth care utilizationMini Asthma QualityQuality of lifeFinal followUsual careAsthma QualityExpiratory volumeInhaler useSymptom diaryTreat analysisCare utilizationSymptom scoresAsthma managementClinical indicesLife QuestionnaireClinical trialsIyengar yogaAsthmaControl groupPilot study